More News

31 July 2013

AstraZeneca and FibroGen collaborate to develop and commercialise FG-4592, a treatment for anaemia in chronic kidney disease and end-stage renal disease

30 July 2013

REGENX Biosciences and Audentes Therapeutics Enter Into Exclusive License Agreement for Development of Treatments for Serious, Rare Muscle Diseases Using NAV(TM) Vectors

30 July 2013

Nerviano Medical Sciences and Servier announce a Collaboration and License Agreement for a Novel Anticancer Drug

30 July 2013

Array BioPharma And Celgene Corporation Announce Strategic global R&D Collaboration To Advance Medical Innovation To Benefit Patients

29 July 2013

Kolltan Enters into License and Option Agreement with MedImmune

29 July 2013

Bristol-Myers Squibb and Samsung BioLogics Announce Biopharmaceutical Manufacturing Relationship

29 July 2013

Acetylon Pharmaceuticals and Celgene Corporation Announce an Exclusive Strategic Collaboration to Advance the Science of Epigenetics

29 July 2013

Perrigo Company to Acquire Elan Corporation, plc for US$8.6 Billion, Establishing Premier Global Healthcare Company

26 July 2013

Biogen Idec and Adimab Expand Collaboration

26 July 2013

Adimab Announces First Antibody Technology Transfer and License Agreement with GlaxoSmithKline

26 July 2013

PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals

25 July 2013

PHYLOGICA AND CUBIST COLLABORATE TO EVALUATE ANTIMICROBIAL PHYLOMERS

25 July 2013

Teva and Lonza Announce Mutual Decision to Discontinue Biologics Joint Venture

25 July 2013

Transition Therapeutics Enters Osteoarthritis License and Collaboration Agreement with Lilly

24 July 2013

Harbour Antibodies BV Raises €2.5M ($3.3M) to Accelerate the Development of Monoclonal Antibody Therapies

23 July 2013

China Becoming Pharma Production Hub

18 July 2013

Bausch + Lomb Acquires Option to License New Compound to Treat Dry Eye Syndrome (DES)

18 July 2013

Ensemble Therapeutics and Alexion Initiate Collaboration to Discover Macrocycle Drug Candidates Targeting Patients with Severe and Ultra-Rare Disorders

17 July 2013

Alkermes Unveils Three New Drug Candidates Demonstrating Productivity of Its R&D Capabilities

17 July 2013

Spectrum Pharmaceuticals Acquires Talon Therapeutics

17 July 2013

Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform

17 July 2013

Paladin Labs Inc. Acquires Allon Therapeutics Inc.

16 July 2013

Asklepios Enters Cross-License Agreement with Genzyme

16 July 2013

Argenta and Pcovery Announce Drug Discovery Collaboration

16 July 2013

Auxilium Pharmaceuticals, Inc. And Swedish Orphan Biovitrum AB (publ) Enter A Collaboration Agreement For XIAPEX In 71 Eurasian And African Countries

15 July 2013

ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer

15 July 2013

ARTES Biotechnology and Bio Farma Announce Collaboration in Vaccine Development

15 July 2013

Ipsen Announce a Sponsored Research Agreement with Harvard Medical School to Discover Novel Engineered Botulinum Toxins for Serious Neurologic Diseases

15 July 2013

Ipsen strengthens its neurology R&D capabilities with the acquisition of Syntaxin, a leader in recombinant botulinum toxin technology

12 July 2013

Medicago announces agreement to be acquired by Mitsubishi Tanabe Pharma in a transaction valued at USD 357M

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

B7-H4 Targeted Antibody Therapy Pipeline Review

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

CCR8-Targeted Antibody Immunotherapy Pipeline Review

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Report Package: “Drug the Undruggable” Technologies

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics